DMII Q4 2025 Earnings Report — Drugs Made In America Acquisition II Corp. Ordinary Shares Revenue & Financial Results | Market Cap Arena

Drugs Made In America Acquisition II Corp. Ordinary SharesDMII

Q4 2025 Earnings

Reported April 15, 2026NEW

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	Q4 2025	Q3 2025	Q4 2024	QoQ Change	YoY Change
Revenue	$0	$0	—	—	—
Op. Income	-$1M	-$155.5K	—	-573.6%	—
EPS (Diluted)	$0.17	$-0.02	—	1100.0%	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$0
Selling & Marketing	$0
General & Administrative	$235.5K
SG&A Expenses	$235.5K
Other Expenses	$812.1K
Operating Expenses	$1M
Cost & Expenses	$1M
OPERATING INCOME	-$1M
Interest Income	-$109.4K
Interest Expense	$0
Other Income/Expenses	$5M
INCOME BEFORE TAX	$4M
Income Tax Expense	$0
Net Income from Continuing Ops	$4M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$4M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$4M
D&A	$0
EBIT	-$1M
EBITDA	-$1M
EPS	$0
EPS Diluted	$0

Balance Sheet

Item	Amount
Cash & Equivalents	$223
Short-Term Investments	$0
Net Receivables	$0
Inventory	$0
Other Current Assets	$0
TOTAL CURRENT ASSETS	$26.0K
PP&E (Net)	$0
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$505M
Tax Assets	$0
Other Non-Current Assets	$0
TOTAL NON-CURRENT ASSETS	$505M
TOTAL ASSETS	$505M
Account Payables	$99.4K
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$201.5K
TOTAL CURRENT LIABILITIES	$300.9K
Long-Term Debt	$0
Deferred Revenue NC	$18M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$0
TOTAL NON-CURRENT LIABILITIES	$18M
TOTAL LIABILITIES	$18M
Common Stock	$505M
Additional Paid-In Capital	$0
Retained Earnings	-$18M
Treasury Stock	$0
Accum. Other Comp. Income	$0
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$487M
Minority Interest	$0
TOTAL EQUITY	$487M
TOTAL LIABILITIES & EQUITY	$505M
Total Debt	$0
Net Debt	-$223